Annals of the Rheumatic Diseases

Discussion New SLE classification criteria were developed with support by both the ACR and EULAR. Through a four-phase, iterative process, we have defined an additive, weighted multicriteria system that produces a measure of the relative probability that an individual can be classified as SLE. The system defines a threshold above which experts would classify cases as SLE for the purpose of research studies.

The treatment target should be clinical remission/inactive disease of musculoskeletal (arthritis, dactylitis, enthesitis, axial disease) and extra-articular manifestations. This bullet point previously read: ‘A major treatment target should be clinical remission/inactive disease of musculoskeletal involvement (arthritis, dactylitis, enthesitis, axial disease), taking extra-articular manifestations into consideration’.

Discussion The EULAR Task Force formulated five OPS and eight PTC relevant to the initiation of targeted therapies in patients with IA and a history of cancer. Seven out of eight PTC concern patients in cancer remission. PTC 8 concerns patients not in cancer remission.

Discussion The EULAR Task Force formulated five OPS and eight PTC relevant to the initiation of targeted therapies in patients with IA and a history of cancer. Seven out of eight PTC concern patients in cancer remission. PTC 8 concerns patients not in cancer remission.

Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Conclusions and future perspectives This international initiative developed a first consensus statement regarding the disease definition of adults with SBI. It was agreed by the panel collectively to label this disease spectrum as CNO in adults (adult CNO), and no longer use terms like SAPHO syndrome, SCCH, PAO and CRMO. Building on this shared definition and name, the panel developed a first set of multidisciplinary consensus recommendations for diagnosis and treatment of adult CNO.

Abstract Objective To assess the efficacy/safety of ivarmacitinib, a selective Janus kinase (JAK) 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Methods Patients were randomised (1:1:1) to receive either placebo (n=188), ivarmacitinib 4 mg (n=189) or ivarmacitinib 8 mg (n=189) once daily, with background csDMARDs allowed.

Feist E, Fleischmann RM, Fatenejad S, et al. Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment. Annals of the Rheumatic Diseases 2024;83:1454-1464. The correct figures 2 and 3 including descriptions provided on y-axis are below:

ML and DR are joint first authors. Handling editor Josef S Smolen X @doronrimar@gmail.com Contributors ML and DR contributed equally to this paper. ML, DR, PD, EJ, RSF, AS and AA conceived the idea and prepared the treatment protocol. ML, DR, PD, EJ and AA and wrote the letter. OI prepared the CAR-T cells. MDS and IE performed the radiological assessment of the patient. TS performed the pathological analysis of biopsy. GS, RM, RY, NST and ID completed patient assessments.

Systemic lupus erythematosus Pharmacodynamics of the S1P1 receptor modulator cenerimod in a phase 2b randomised clinical trial in patients with moderate to severe SLE Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.